Typical metastases, atypical course of the disease and morphology
https://doi.org/10.62546/3034-1477-2023-1-1-63-73
Abstract
The process of tumor differentiation is a central aspect of the histopathological classification of solid malignancies and is closely related to the biological behavior of the tumor (poorly differentiated tumors/dedifferentiated tumors are known to be more aggressive than more differentiated tumors). The mechanisms by which tumor cell differentiation is disrupted are poorly understood, but pathologists and molecular tumor biologists have introduced the concept of dedifferentiation to explain the phenotypic changes that occur in solid tumors. In this review, we discuss a case of detection of dedifferentiated cancer, where even with the help of molecular testing of a tumor sample, we were not completely able to unambiguously determine the original source of the process, which entailed difficulties in choosing treatment tactics. And the main question that we asked ourselves during the treatment process: should treatment be based on molecular markers identified in the tumor, or should treatment be carried out according to the recommendations for the treatment of tumors of an undetected primary location with empirically selected chemotherapy?
About the Authors
N. P. Belyak
St. Petersburg State University; City Clinical Oncology Centre
Russian Federation
Russian Federation
Belyak Natalia Petrovna — PhD Med, associate professor at Dept of Oncology; head of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Author ID 778562
St. Petersburg
A. V. Androsova
St. Petersburg State University; City Clinical Oncology Centre
Russian Federation
Russian Federation
Androsova Aleksandra Valeryevna — post-graduate studen; medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
St. Petersburg
References
1. Reubi J.C., Zimmermann A., Jonas S., Waser B., Neuhaus P., Läderach U., Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas // Gut. 1999. Vol. 45. Р. 766–774.
2. Reynaert H., Rombouts K., Vandermonde A., Urbain D., Kumar U., Bioulac-Sage P., Pinzani M., Rosenbaum J., Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma // Gut. 2004. Vol. 53. Р. 1180–1189.
3. Blaker M., Schmitz M., Gocht A., Burghardt S., Schulz M., Broring D.C., Pace A., Greten H., de Weerth A. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas // J. Hepatol. 2004. Vol. 41. Р. 112–118.
4. Xie Y.M., Yan L.N., Wei B., Guo M.M., Tang C.W. Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration // Ai Zheng. 2007. Vol. 26. Р. 688–692 (in Chinese).
5. Koc E.U., Ozgur T., Yerci O., Gurel S. Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) expression in hepatocellular carcinoma // Hepatogastroenterology. 2013. Vol. 60. Р. 1693–1697.
6. Kaemmerer D., Schindler R., Mußbach F., Dahmen U., Altendorf-Hofmann A., Dirsch O., Sänger J., Schulz S., Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets // BMC Cancer. 2017. Vol. 17. Р. 896.
7. Li S., Liu Y., Shen Z. Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas // Hepatogastroenterology. 2012. Vol. 59. Р. 2054–2058.
8. Liu Y., Jiang L., Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment // Oncology Letters. 2013. Vol. 6. Р. 821–828.
9. Barbare J.C., Bouche O., Bonnetain F., Dahan L., Lombard-Bohas C., Faroux R., Raoul J.L., Cattan S., Lemoine A., Blanc J.F. et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study // European Journal of Cancer. 2009. Vol. 45. Р. 1788–1797.
10. Prete S.D., Montella L., CaragliaM., Maiorino L., Cennamo G., Montesarchio V., Piai G., Febbraro A., Tarantino L., Capasso E. et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study // Cancer Chemotherapy and Pharmacology. 2010. Vol. 66. Р. 837–844.
11. Ji X.Q., Ruan X.J., Chen H., Chen G., Li S.Y., Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials // Medical Science Monitor. 2011. Vol. 17. RA169–RA176.
12. Jia W., Feng K., Fan P., Fan G., Yang S., Zhang T., Wei Q., Qian L. Post-TACE combination therapy of heparin and octreotide results in decreased tumor metastasis in extrahepatic tumorigenesis // Cell Biochemistry and Biophysics. 2012. Vol. 62. Р. 35–40.
13. Tong H., Wei B., Chen S., Xie Y.M., Zhang M.G., Zhang L.H., Huang Z.H., Tang C.W. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study // Oncotarget. 2017. Vol. 8. Р. 48303–48312.
14. Prete S.D., Montella L., Caraglia M., Maiorino L., Cennamo G., Montesarchio V., Piai G., Febbraro A., Tarantino L., Capasso E., Palmieri G., Guarrasi R., Bianco M., Mamone R., Savastano C., Pisano A., Vincenzi B., Sabia A., D’Agostino A., Faiola V., Addeo R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR study // Cancer Chemother Pharmacol. 2010. Vol. 66. Р. 837–844.
15. Becker G., Allgaier H.P., Olschewski M., Zahringer A., Blum H.E.; HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study // Hepatology. 2007. Vol. 45. Р. 9–15.
16. Sanoff H.K., Kim R., Ivanova A., Alistar A, McRee A.J., O’Neil B.H. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma // Invest New Drugs. 2015. Vol. 33. Р. 505–509.
17. Feun L.G., Wangpaichitr M., Li Y.Y., Kwon D., Richman S.P., Hosein P.J., Savaraj N. Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma // J. Hepatocell Carcinoma. 2018. Vol. 5. Р. 9–15.
18. Tsagarakis N.J., Drygiannakis I., Batistakis A.G., Kolios G., Kouroumalis E.A. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells // World J. Gastroenterol. 2011. Vol. 17. Р. 313–321.
19. Park J.W., Chen M., Colombo M., Roberts L.R., Schwartz M., Chen P.J., Kudo M., Johnson P., Wagner S., Orsini L.S., Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study // Liver Int. 2015. Sep; Vol. 35, No. 9. Р. 2155–2166. doi: 10.1111/liv.12818. Epub 2015 Mar 25. PMID: 25752327; PMCID: PMC4691343.
20. Kim B.K., Han K.H., Ahn S.H. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection // Oncology. 2011. Vol. 81, Suppl. 1. Р. 41–49.
21. Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases // Hepatology. 2018. Vol. 68. Р. 723–750.
22. Llovet J.M., Ricci S., Mazzaferro V. et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma // N. Engl. J. Med. 2008. Jul. 24; Vol. 359(4. Р. 378–390. doi: 10.1056/NEJMoa0708857. PMID: 18650514.
23. Cheng A.L., Kang Y.K., Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial // Lancet Oncol. 2009. Jan; Vol. 10, No. 1. Р. 25–34. doi: 10.1016/S1470–2045(08)70285–7. Epub 2008 Dec 16. PMID: 19095497.
24. Vilchez V., Turcios L., Marti F., Gedaly R. Targeting Wnt/<b>-catenin pathway in hepatocellular carcinoma treatment // World J. Gastroenterol. 2016. Vol. 22, No. 2. Р. 823–832.
25. Chen X., Calvisi D.F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research // Am.J.Pathol. 2014. Apr; Vol. 184, No. 4. Р. 912–923. doi: 10.1016/j.ajpath.2013.12.002. Epub 2014 Jan 28. PMID: 24480331; PMCID: PMC3969989
Review
For citations:
Belyak N.P., Androsova A.V. Typical metastases, atypical course of the disease and morphology. Clinical Case in Oncology. 2023;1(1):63-73. (In Russ.) https://doi.org/10.62546/3034-1477-2023-1-1-63-73
Views:
338
Email this article 